Your browser doesn't support javascript.
loading
A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students.
Lee, Christine C; Segaloff, Hannah E; Cole, Devlin; Rosenblum, Hannah G; Morgan, Clint N; Somers, Tarah; Desamu-Thorpe, Rodel; Foster, Monique A; Currie, Dustin; Ruff, Jeanne; Payne, David; Whyte, Thomas J; Abedi, Glen R; Bigouette, John Paul; Kahrs, Juliana; Langolf, Kimberly; Remington, Patrick; Sterkel, Alana; Kelly, Patrick; Westergaard, Ryan P; Bateman, Allen C; Hsu, Christopher H; Tate, Jacqueline E; Kirking, Hannah L.
Afiliación
  • Lee CC; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA. pfx6@cdc.gov.
  • Segaloff HE; Laboratory Leadership Service, CDC, Atlanta, GA, 30329, USA. pfx6@cdc.gov.
  • Cole D; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA.
  • Rosenblum HG; Epidemic Intelligence Service, CDC, Atlanta, GA, 30329, USA.
  • Morgan CN; Wisconsin Department of Health Services, Madison, WI, 53703, USA.
  • Somers T; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Desamu-Thorpe R; University Health Services, University of Wisconsin-Madison, Madison, WI, 53705, USA.
  • Foster MA; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA.
  • Currie D; Epidemic Intelligence Service, CDC, Atlanta, GA, 30329, USA.
  • Ruff J; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA.
  • Payne D; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA.
  • Whyte TJ; Agency for Toxic Substances and Disease Registry (ATSDR), CDC, Atlanta, GA, 30341, USA.
  • Abedi GR; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA.
  • Bigouette JP; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA.
  • Kahrs J; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA.
  • Langolf K; Epidemic Intelligence Service, CDC, Atlanta, GA, 30329, USA.
  • Remington P; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA.
  • Sterkel A; Epidemic Intelligence Service, CDC, Atlanta, GA, 30329, USA.
  • Kelly P; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA.
  • Westergaard RP; Laboratory Leadership Service, CDC, Atlanta, GA, 30329, USA.
  • Bateman AC; Wisconsin State Laboratory of Hygiene, Madison, WI, 53718, USA.
  • Hsu CH; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA.
  • Tate JE; CDC COVID-19 Response Team, 1600 Clifton Rd. NE, Mailstop H23-6, Atlanta, GA, USA.
  • Kirking HL; Epidemic Intelligence Service, CDC, Atlanta, GA, 30329, USA.
BMC Infect Dis ; 22(1): 314, 2022 Mar 31.
Article en En | MEDLINE | ID: mdl-35361140
BACKGROUND: To improve understanding of the antibody response to SARS-CoV-2 infection, we examined seroprevalence, incidence of infection, and seroconversion among a cohort of young adults living on university campuses during the fall of 2020. METHODS: At the beginning (semester start) and end (semester end) of an 11-week period, serum collected from 107 students was tested using the qualitative Abbott Architect SARS-CoV-2 IgG and AdviseDx SARS-CoV-2 IgG II assays. Results were matched to interim weekly surveillance viral testing and symptom data. RESULTS: With the SARS-CoV-2 IgG assay, 15 (14.0%) students were seropositive at semester start; 29 (27.1%) students were seropositive at semester end; 10 (9.3%) were seropositive at both times. With the AdviseDx SARS-CoV-2 IgG II assay, 17 (16.3%) students were seropositive at semester start, 37 (35.6%) were seropositive at semester end, and 16 (15.3%) were seropositive at both times. Overall, 23 students (21.5%) had positive viral tests during the semester. Infection was identified by serial testing in a large majority of individuals who seroconverted using both assays. Those seropositive at semester end more frequently reported symptomatic infections (56.5%) than asymptomatic infections (30.4%). CONCLUSION: Differences between antibody targets were observed, with more declines in antibody index values below the threshold of positivity with the anti-nucleocapsid assay compared to the anti-spike assay. Serology testing, combined with serial viral testing, can detect seroconversions, and help understand the potential correlates of protection provided by antibodies to SARS-CoV-2.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Qualitative_research / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Qualitative_research / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido